乳腺癌骨转移的影像学诊断进展

张雪辉; 杨贵生; 肖国有; 张雪辉; 杨贵生; 肖国有

doi:10.3760/cma.j.issn.1673-4114.2017.04.008

[1]

DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013[J]. CA Cancer J Clin, 2014, 64(1):52-62. DOI:10.3322/caac.21203.

[2]

Zhou C, He JJ, Li J, et al. A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer[J/OL]. PLoS One, 2014, 9(7):e100159[2017-01-12]. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0100159. DOI:10.1371/journal.pone.0100159.

[3]

Siegel R, Naishadham D, Jemal A. Cancer Statistics[J]. CA Cancer J Clin, 2013, 63(1):11-30. DOI:10.3322/caac.21166.

[4]

贺捷, 陈万青. 2012中国肿瘤登记年报[M].北京:军事医学科学出版社, 2012:28.

He J, Chen WQ. 2012 Annual Report of Cancer Registry in China[M]. Beijing:Press of Military Medical Sciences, 2012:28.

[5]

Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12):2893-2917. DOI:10.1002/ijc.25516.

[6]

Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China[J].Lancet Oncol, 2014, 15(7):e279-e289. DOI:10.1016/S1470-2045(13)70567-9.

[7]

张敏璐, 黄哲宙, 郑莹.中国2008年女性乳腺癌发病、死亡和患病情况的估计及预测[J].中华流行病学杂志, 2012, 33(10):1049-1051. DOI:10.3760/cma.j.issn.0254-6450.2012.10.012.
Zhang ML, Huang ZZ, Zheng Y. Estimates and prediction on incidence, mortality and prevalence of breast cancer in China, 2008[J]. Chin J Epidemiol, 2012, 33(10):1049-1051. doi: 10.3760/cma.j.issn.0254-6450.2012.10.012

[8]

江泽飞, 陈佳艺, 牛晓辉, 等.乳腺癌骨转移和骨相关疾病临床诊疗专家共识(2014版)[J].中华医学杂志, 2015, 95(4):241-247. DOI:10.3760/cma.j.issn.0376-2491.2015.04.001.
Jiang ZF, Chen JY, Niu XH, et al. Expert consensus on clinical diagnosis and treatment of bone metastasis and bone related diseases in breast cancer(2014 edition)[J]. Nat Med J China, 2015, 95(4):241-247. doi: 10.3760/cma.j.issn.0376-2491.2015.04.001

[9]

Lipton A, Cook RJ, Major P, et al. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity[J]. Oncologist, 2007, 12(9):1035-1043. DOI:10.1634/theoncologist.12-9-1035.

[10]

Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity[J]. J Thorac Oncol, 2008, 3(3):228-236. DOI:10.1097/JTO.0b013e3181651c0e.

[11]

于世英.恶性肿瘤骨转移的诊断与治疗[M].北京:中国协和医科大学出版社, 2012:25-35.

Yu SY. Diagnosis and treatment of bone metastases in malignant tumor[M]. Beijing:Peking Union Medical College Press, 2012:25-35.

[12]

李林, 赵祯, 郭兴.恶性肿瘤骨转移影像学诊断[J].中华核医学杂志, 2006, 26(5):315-318. DOI:10.3760/cma.j.issn.2095-2848. 2006.05.023.
Li L, Zhao Z, Guo X. Malignant tumor imaging in the diagnosis of bone metastases[J]. Chin J Nucl Med, 2006, 26(5):315-318. doi: 10.3760/cma.j.issn.2095-2848.2006.05.023

[13]

郑飞波, 刘晚霞, 丁月云, 等.转移性骨肿瘤的影像学诊断进展[J].实用医学影像杂志, 2015, 16(3):253-255. DOI:10.16106/j.cnki.cn14-1281/r.2015.03.025.
Zheng FB, Liu WX, Ding YY, et al. The progress of imaging diagnosis of metastatic bone tumor[J]. J Pract Med Imaging, 2015, 16(3):253-255. doi: 10.16106/j.cnki.cn14-1281/r.2015.03.025

[14]

邱艳芳, 赵艳萍.骨转移瘤的影像学诊断研究现状[J].海南医学, 2015, 26(4):543-546. DOI:10.3969/j.issn.1003-6350.2015.04. 0196.
Qiu YF, Zhao YP. Research status of imaging diagnosis of osseous metastatic tumor[J]. Hainan Med J, 2015, 26(4):543-546. doi: 10.3969/j.issn.1003-6350.2015.04.0196

[15]

齐红艳, 孙逊, 安锐.骨转移瘤影像学检查方法及相关进展[J].华中科技大学学报:医学版, 2015, 44(1):121-124. DOI:10.3870/j.issn.1672-0741.2015.01.025.
Qi HY, Sun X, An R. Bone metastases imaging examnination method and the related progress[J]. Acta Med Univ Sci Technol Huazhong, 2015, 44(1):121-124. doi: 10.3870/j.issn.1672-0741.2015.01.025

[16]

王兵, 董越, 郑邵微, 等. CT能谱成像鉴别诊断肺癌成骨性转移瘤与骨岛的价值[J].中国医学影像技术, 2014, 30(10):1552-1556.
Wang B, Dong Y, Zheng SW, et al. Spectral CT imaging in differential diagnosis of osteoblastic metastases and bone islands in patients with lung cancer[J]. Chin J Med Imaging Technol, 2014, 30(10):1552-1556.

[17]

胡鸿, 唐刚华, 聂大红.乳腺癌分子显像研究进展[J].国际放射医学核医学杂志, 2015, 39(1):91-95. DOI:10.3760/cma.j.issn.1673-4114. 2015.01.019.
Hu H, Tang GH, Nie DH. Progress on molecular imaging of breast cancer[J]. Int J Radiat Med Nucl Med, 2015, 39(1):91-95. doi: 10.3760/cma.j.issn.1673-4114.2015.01.019

[18]

赵应满, 陈峰, 许琴, 等. MR弥散加权成像骨髓对比率与核素骨显像在脊柱转移瘤诊断中的价值[J].中国脊柱脊髓杂志, 2013, 23(9):810-814. DOI:10.3969/j.issn.1004-406X.2013.09.09.
Zhao YM, Chen F, Xu Q, et al. Comparison of MR diffusion weighted imaging bone marrow ratio and radionuclide bone imaging in the diagnosis of spine metastasis[J]. Chin J Spine Spinal Cord, 2013, 23(9):810-814. doi: 10.3969/j.issn.1004-406X.2013.09.09

[19]

王警建, 崔尊社, 李娜.全身MRI和骨扫描诊断乳腺癌骨转移比较[J].湖北医药学院学报, 2011, 30(5):458-460.
Wang JJ, Cui ZS, Li N. Comparison of whole-body MRI and bone scintigraphy for diagnosing osseous metastasis in patients with breast cancer[J]. J Hubei Univ Med, 2011, 30(5):458-460.

[20]

Gutzeit A, Doert A, Froehlich JM, et al. Comparison of difusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma[J]. Skeletal Radiol, 2010, 39(4):333-343. DOI:10.1007/s00256-009-0789-4.

[21]

孙梦恬, 程敬亮, 张勇, 等.背景抑制全身扩散加权成像对不同类型骨转移瘤诊断价值的探讨[J].临床放射学杂志, 2013, 32(2):236-241.
Sun MT, Cheng JL, Zhang Y, et al. The diagnostic value of DWIBS in various types of bone metastasis[J]. J Clin Radiol, 2013, 32(2):236-241.

[22]

汪建强, 曹春晓, 杨琦, 等. ¹⁸F-FDG SPECT/CT符合线路显像、⁹⁹Tc^m-MDP骨显像及MRI对脊柱转移瘤诊断效能的对比[J].中华核医学与分子影像杂志, 2015, 35(5):403-404. DOI:10.3760/cma.j.issn.2095-2848.2015.05.015.
Wang JQ, Cao CX, Yang Q, et al. The comparsion of ¹⁸F-FDG SPECT/CT, ⁹⁹Tc^m-MDP bone scan and MRI in the diagnosis of spinal metastases[J]. Chin J Nucl Med Mol Imaging, 2015, 35(5):403-404. doi: 10.3760/cma.j.issn.2095-2848.2015.05.015

[23]

Chakraborty D, Bhattacharya A, Mete UK, et al. Comparison of ¹⁸F fluoride PET/CT and ^99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma[J]. Clin Nucl Med, 2013, 38(8):616-621. DOI:10.1097/RLU.0b013e31828da5cc.

[24]

董科, 傅健飞, 楼菁菁, 等.分子影像SPECT/CT对乳腺癌骨转移的临床应用价值[J].中国临床医学影像杂志, 2015, 26(7):465-468.
Dong K, Fu JF, Lou JJ, et al. The clinical application value of molecular imaging SPECT/CT for bone metastases from breast cancer[J]. J Chin Clin Med Imaging, 2015, 26(7):465-468.

[25]

彭东, 徐可为, 王荣辉, 等. SPECT/CT融合显像诊断肿瘤骨转移的临床价值[J].广西医学, 2014, 36(8):1153-1155. DOI:10.11675/j.issn.0253-4304.2014.08.44.
Peng D, Xu KW, Wang RH, et al. The value of SPECT/CT fusion imaging in diagnosis of tumor bone metastases[J]. Guangxi Med J, 2014, 36(8):1153-1155. doi: 10.11675/j.issn.0253-4304.2014.08.44

[26]

Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography[J]. J Clin Oncol, 1999, 17(8):2381-2389. DOI:10.1200/JCO.1999. 17.8.2381.

[27]

Ohta M, Tokuda Y, Suzuki Y, et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer:comparison with ⁹⁹Tc^m-MDP bone scintigraphy[J]. Nucl Med Commun, 2001, 22(8):875-879. DOI:10.1097/00006231-200108000-00005.

[28]

郭粹, 陈虞梅, 童林军, 等. PET/CT在乳腺癌疗效监测中的作用[J].国际医学放射学杂志, 2016, 39(2):146-150, 161. DOI:10.19300/j.2016.Z3667.
Guo C, Chen YM, Tong LJ, et al. The role of PET/CT in monitering the treatment effect of breast cancer[J]. Int J Med Radiol, 2016, 39(2):146-150, 161. doi: 10.19300/j.2016.Z3667

[29]

Minamimoto R, Loening A, Jamali M, et al. Prospective comparison of ^99mTc-MDP scintigraphy, combined ¹⁸F-NaF and ¹⁸F-FDG PET/CT, and Whole-Body MRI in patients with breast and prostate cancer[J]. J Nucl Med, 2015, 56(12):1862-1868. DOI:10.2967/jnumed.115. 162610.

[30]

辛军, 孙洪赞, 王鹏远, 等.同机PET/MR显像临床应用价值初探[J].中华核医学与分子影像杂志, 2014, 34(6):428-432. DOI:10.3760/cma.j.issn. 2095-2848. 2014.06.003.
Xin J, Sun HZ, Wang PY, et al. Preliminary clinical application of hybrid PET/MR[J]. Chin J Nucl Med Mol Imaging, 2014, 34(6):428-432. doi: 10.3760/cma.j.issn.2095-2848.2014.06.003